Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $12.43.
TSVT has been the subject of a number of research reports. The Goldman Sachs Group downgraded 2seventy bio from a “neutral” rating to a “sell” rating and lowered their price target for the company from $5.00 to $2.00 in a research report on Thursday, June 6th. Citigroup boosted their price target on 2seventy bio from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Canaccord Genuity Group raised 2seventy bio to a “strong-buy” rating in a report on Thursday, May 9th. Canaccord Genuity Group lowered their target price on 2seventy bio from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, May 9th. Finally, Wedbush reissued a “neutral” rating and issued a $5.00 price objective on shares of 2seventy bio in a report on Thursday, June 27th.
Check Out Our Latest Report on 2seventy bio
Institutional Investors Weigh In On 2seventy bio
2seventy bio Stock Down 2.9 %
Shares of NASDAQ:TSVT opened at $4.77 on Friday. The company has a market cap of $245.18 million, a P/E ratio of -1.10 and a beta of 1.76. 2seventy bio has a 52 week low of $1.53 and a 52 week high of $10.89. The business has a fifty day simple moving average of $4.21 and a 200-day simple moving average of $4.57.
2seventy bio (NASDAQ:TSVT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The business had revenue of $12.44 million during the quarter, compared to analysts’ expectations of $11.93 million. 2seventy bio had a negative net margin of 313.51% and a negative return on equity of 67.59%. Sell-side analysts expect that 2seventy bio will post -0.93 earnings per share for the current fiscal year.
2seventy bio Company Profile
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than 2seventy bio
- Using the MarketBeat Stock Split Calculator
- Real Estate Stock Signals a Boom in Manufacturing Activity
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- What is the Shanghai Stock Exchange Composite Index?
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.